When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Content provided by Docs Who Lift. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Docs Who Lift or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Zepbound versus Wegovy
MP3•Episode home
Manage episode 482242777 series 3363968
Content provided by Docs Who Lift. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Docs Who Lift or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
- Tirzepatide is more effective for weight loss than semaglutide.
- Cost-effectiveness is crucial in prescribing weight loss medications.
- Patients with severe obesity should receive more expensive medications for better outcomes.
- Both medications show significant benefits for obesity-related conditions.
- Long-term studies indicate sustained weight loss with both drugs.
- Gender differences affect weight loss outcomes with these medications.
- Safety profiles show tirzepatide may be better tolerated than semaglutide.
- The need for affordable drug pricing is emphasized.
- Clinical benefits extend beyond weight loss to include metabolic health.
- Future studies are needed to confirm cardiovascular benefits of tirzepatide.
Click here to join Dr. Spencer's new online clinic
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
138 episodes
MP3•Episode home
Manage episode 482242777 series 3363968
Content provided by Docs Who Lift. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Docs Who Lift or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
- Tirzepatide is more effective for weight loss than semaglutide.
- Cost-effectiveness is crucial in prescribing weight loss medications.
- Patients with severe obesity should receive more expensive medications for better outcomes.
- Both medications show significant benefits for obesity-related conditions.
- Long-term studies indicate sustained weight loss with both drugs.
- Gender differences affect weight loss outcomes with these medications.
- Safety profiles show tirzepatide may be better tolerated than semaglutide.
- The need for affordable drug pricing is emphasized.
- Clinical benefits extend beyond weight loss to include metabolic health.
- Future studies are needed to confirm cardiovascular benefits of tirzepatide.
Click here to join Dr. Spencer's new online clinic
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
138 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.